What is KYRNF stock price today?

KYRNF (KYORIN Pharmaceutical Co., Ltd.) stock is trading at $10.47 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is KYRNF stock going up or down today?

KYRNF stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy KYRNF stock now?

The decision to buy KYRNF depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is KYRNF a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for KYRNF based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is KYRNF stock overvalued or undervalued?

KYRNF currently trades at a P/E ratio of 10.26, which may suggest attractive valuation. Our DCF calculator provides intrinsic value estimates to help determine if KYRNF is fairly priced.

What is KYRNF's P/E ratio?

KYRNF has a price-to-earnings (P/E) ratio of 10.26, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is KYRNF's market cap?

KYRNF (KYORIN Pharmaceutical Co., Ltd.) has a market capitalization of $0.60 billion, making it a small-cap stock.

What is KYRNF's price to book ratio?

KYRNF trades at a price-to-book (P/B) ratio of 0.63, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does KYRNF pay dividends?

Yes, KYRNF pays dividends with a current yield of 0.04%. Dividend payments provide income for investors in addition to potential stock price appreciation.

What is KYRNF's dividend yield?

KYRNF's dividend yield is 0.04%, calculated as annual dividends divided by the current stock price. This represents the annual return from dividends alone.

Is KYRNF stock a good long-term investment?

KYRNF's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is KYRNF's revenue growth rate?

KYRNF has shown revenue growth of -0.0% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, KYRNF is profitable with a profit margin of 0.1%. This indicates the company generates 0.1 cents of profit for every dollar of revenue.

What are the risks of investing in KYRNF?

Key risks for KYRNF include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does KYRNF compare to its competitors?

Compare KYRNF to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize KYRNF's performance and positioning.

What is KYRNF's stock price target for 2026?

Our AI model provides price targets for KYRNF based on fundamental analysis: Bull case $13.61 (+30%), Base case $12.04 (+15%), Bear case $9.42 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about KYRNF?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for KYRNF. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is KYRNF's next earnings report?

KYRNF reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

KYRNF - KYORIN Pharmaceutical Co., Ltd.

NYSE * Healthcare * Drug Manufacturers - Specialty & Generic

$10.47

+$0.00 (+0.00%)

About KYORIN Pharmaceutical Co., Ltd.

KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Lyfuna for cough treatment; Desalex, an antiallergic agent; Beova, and Uritos KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex and Mometasone KYORIN, which are used as allergic rhinitis therapeutic agents; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; and prescription medicines and quasi-drugs, and diagnostics business. In addition, the company offers subcontracted drug manufacturing services. It has development and commercialization agreement with Hyfe Inc. for digital therapeutics (DTx) for chronic cough. The company was formerly known as KYORIN Holdings, Inc. KYORIN Pharmaceutical Co., Ltd. was founded in 1923 and is headquartered in Tokyo, Japan.

KYRNF Key Statistics

Market Cap

$601.52M

P/E Ratio

10.26

P/B Ratio

0.63

EPS

$1.02

Dividend Yield

0.04%

Revenue Growth

-0.0%

Profit Margin

0.1%

Employees

1,998

How KYRNF Compares to Peers

KYRNF has the lowest P/E ratio in Drug Manufacturers - Specialty & Generic, suggesting it may be the most undervalued

KYRNF is the smallest among peers, which may offer higher growth potential

P/E Rank

of 6

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
KYRNF(This stock)	$601.52M	10.3	-0%	0.1%	-
LLYEli Lilly	$809.09B	39.3	0%	0.3%	vs LLY
JNJJohnson &	$575.17B	21.8	0%	0.2%	vs JNJ
PFEPfizer Inc	$154.67B	20.0	-0%	0.1%	vs PFE
MRKMerck &	$291.50B	16.2	0%	0.3%	vs MRK
ABBVAbbvie Inc	$368.65B	87.6	0%	0.1%	vs ABBV

KYORIN Pharmaceutical Co., Ltd. Company Information

Headquarters: 1-3-7, Otemachi, Tokyo, Japan, 100-0004, undefined
Website: www.kyorin-pharm.co.jp
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

About KYORIN Pharmaceutical Co., Ltd.

KYRNF Key Statistics

How KYRNF Compares to Peers

KYORIN Pharmaceutical Co., Ltd. Company Information

Upcoming Events for KYRNF